Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Schizophrenia
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Schizophrenia
    TopAbstracts in Schizophrenia 09/04/2008 - (DGNews)
    Antipsychotics Significantly Decrease Free Thyroid Hormone Concentrations: Presented at ECNP - (DGDispatch)
    Cognitive and Global Outcome in Schizophrenia Patients Related to Course of Disease, Not Antipsychotic Type: Presented at ECNP - (DGDispatch)
    Presence of Cardiometabolic Risk Factors in Patients on Antipsychotics Does Not Lead to Sufficient Risk Management by Treating Psychiatrists: Presented at ECNP - (DGDispatch)
    All Antipsychotics Increase Risk of Stroke, Patients With Dementia at Double Risk - (DGNews)

    News archive

     Recent webcasts/CME - Schizophrenia
  • Multimodal Management Emphasized in Early-Onset Schizophrenia
  • Improving Functional Outcomes: Assessment and Management of Cognitive Dysfunction in Patients with Schizophrenia

    Webcasts/CME archive

     Recent cases - Schizophrenia
      Diabetic Control and Atypical Antipsychotics: A Case Report
      A Familial Concurrence of Schizophrenia and Gaucher's Disease
      Necrotising Colitis Related to Clozapine? A Rare but Life Threatening Side Effect
      Case Report: Psychosis in an Adolescent with Sickle Cell Disease
      Case Report: Rapidly Fatal Bowel Ischaemia on Clozapine Treatment

      Cases archive
        




      my personal edition > schizophrenia > news
      divider

        E-Mail this DGReview to a colleague

      DGReview


      Haloperidol and Risperidone May Produce Opposite Effects on Human Corticospinal System in Schizophrenic Patients

      A DGReview of :"Excitability of the motor cortex in schizophrenia following typical and atypical antipsychotics: two serial case reports"
      International Journal of Clinical Practice

      01/15/2004
      By Jill Taylor


      Haloperidol and risperidone -- two drugs used for treatment of schizophrenic -- might have a clear difference in pharmacologically-induced changes in corticospinal excitability.

      In a previous electrophysiological investigation of schizophrenia using transcranial magnetic stimulation, Basant K. Puri, MA, MB, BChir, MRCPsych, MRC Clinical Sciences Centre, Hammersmith Hospital, London, United Kingdom, and colleagues observed altered corticospinal inhibition in medicated patients compared with drug-naïve patients.

      Using similar techniques, these researchers performed a study of the time-course of drug action in two antipsychotic drug-naïve schizophrenic patients, one patient treated with the typical antidopaminergic antipsychotic haloperidol and the other with the atypical antipsychotic risperidone.

      Both subjects were men in their early twenties with first-episode schizophrenia. Immediately after neurophysiological and clinical assessments, one patient began haloperidol treatment at a dose of 6 mg/day, which was increased to 16 mg/day 6 days later for the study duration, and the second patient began risperidone treatment at 2 mg/day, incrementally increased to 6 mg/day for the study duration.

      After initial assessment, the patients were evaluated at intervals of 2 to 11 days up to 6 weeks.

      Symptoms were rated using the Schedule for the Assessment of Positive Symptoms (SAPS) and the Schedule for the Assessment of Negative Symptoms (SANS). Electrophysiological measurements were obtained by electromyograms and electromagnetic stimulation of the cerebral motor cortex.

      Results showed that use of haloperidol was associated with increased overall corticospinal excitability, as evidenced by an increase in motor evoked potential area 4 to 5 weeks after treatment initiation, while risperidone decreased overall corticospinal excitability, as evidenced by a decrease in motor evoked potential area 3 to 4 weeks post-treatment.

      Interestingly, the SAPS score associated with haloperidol improved within a few days of the increase in corticospinal excitability. Alternatively, the SAPS score was reduced 2 to 3 weeks in advance of the decrease in corticospinal excitability associated with risperidone.

      It is likely that the opposite neurophysiological effects are related to the relative dopaminergic and serotonergic actions of the two classes of drug, the investigators write.

      "This electrophysiological approach to the investigation of pharmacological actions of psychotropic agents in the human brain may be informative in the exploration and differentiation between putative antipsychotics," they conclude.
      Int J Clin Pract 2003 Nov;57:9:831-3. "Excitability of the motor cortex in schizophrenia following typical and atypical antipsychotics: two serial case reports"

      E-Mail this DGReview to a colleague   To print, use this version






      All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send